Clinical Trial For People Newly Diagnosed With HIV 2026

We’re excited to announce that we’ve begun enrollment for a new clinical trial for individuals who are either treatment-naive or treatment-experienced but naive to the study drug class. Eligible participants must not have received any antiretroviral therapy (ART) within 12 weeks of screening, including medications used for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP).

  • Between 18 and 65 years of age

  • New diagnosis of HIV-1 Infection or,

  • Previously diagnosed but not taking any HIV-1 medications for the past 12 weeks

  • Not pregnant or breastfeeding, and not wish to become pregnant during the study period

Taking part in this study will last about 25 days, not including the initial screening visit to determine qualification. During this time, there are 10 visits to the study site.

Study assessments could include the following:

  • Collect blood and urine

  • Physical exams

  • Vital signs

  • ECG

  • Taking an investigational study drug

  • Investigational study drug provided at no cost

  • Upon completion of study drug, participants can initiate a Sponsor-provided HIV treatment at no cost for the remainder of the study

  • Access to care by a doctor and close monitoring of your health during the study

  • Reimbursement for travel expenses and compensation for participation

  • Contributing to medical science for HIV

A participating research doctor can give you and/or the subject more information and answer any questions you might have.

A Phase 2b Study 2026

Evaluating Oral VH4524184 Plus Emtricitabine and Tenofovir Alafenamide in treatment-Naïve Persons with HIV-1

Who can join innovate?

Am I Eligible

You MAY be able to join if you:

You MAY NOT be able to join if you:

CONTACT US TODAY

for more information

Layla Garcia, RMA

Clinical Research Coordinator

Joshua Griffin

Clinical Research Coordinator